China Grants Registration Approval for Antibacterial Drug
China's medical products administrator granted Hainan Poly Pharm (SHE:300630) drug registration approval for its vancomycin hydrochloride antibacterial drug, according to a Tuesday filing with the She
Express News | Puli Pharmaceuticals: Trimebutine maleate tablets obtained a consistency evaluation notice from the National Drug Administration (NMPA)
Puri Pharmaceuticals (300630.SZ): Vancomycin hydrochloride for injection obtained registration approval
On May 13, Gelonghui Pharmaceuticals (300630.SZ) announced that the company recently received the drug registration approval for injectable vancomycin hydrochloride issued by the State Drug Administration. Intravenous infusion of this product is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria: sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical trauma and other superficial secondary infections, pneumonia, lung abscesses, empyema, peritonitis, and meningitis. This product can be taken orally for antimicrobial-related pseudomembranous colitis and staphylococcal enterocolitis caused by Clostridium difficile, but injection has not yet been given
CSC Peng Yuan: Concerned about Puli Pharmaceuticals' inability to disclose periodic reports, bond suspensions, and receipt of letters of concern and case filing notices as scheduled
CSC Peng Yuan is concerned that Hainan Puli Pharmaceutical Co., Ltd. is unable to disclose the 2023 annual report and the first quarter report of 2024 within the legal period, and trading of the company's shares and convertible corporate bonds will be suspended from May 6, 2024. In response to the above matters, the Shenzhen Stock Exchange issued a letter of concern to the company. On May 8, 2024, the China Securities Regulatory Commission decided to file a lawsuit against the company. The above incident indicates that the company has problems with information disclosure, internal control, etc., and is expected to have a certain adverse impact on the company's operations, finances, and credit conditions. CSIC Peng Yuan will closely monitor the subsequent developments of the above events and continue
Puli Pharmaceuticals (300630.SZ) received a notice from the China Securities Regulatory Commission to file a case
Puli Pharmaceuticals (300630.SZ) announced that the company received from the China Securities Regulatory Commission on May 8, 2024...
Hainan Poly Pharm Gets GMP Certificate From Saudi Authorities
Hainan Poly Pharm (SHE:300630) secured a good manufacturing practice certificate from the Saudi Arabian Food and Drug Administration, according to a Monday filing with the Shenzhen Stock Exchange. The
Puli Pharmaceuticals (300630.SZ) obtained GMP certification from Saudi Arabian Food and Drug Administration
Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received from the Saudi Food and Drug Administration (...
Bipli Pharmaceuticals (300630.SZ) has not completed its self-inspection of the previous report and is unable to disclose the regular report on schedule. Stock and bond trading was suspended from May 6
Puri Pharmaceuticals (300630.SZ) issued an announcement that the company was unable to meet the legal deadline (April 30, 2024...
Puli Pharmaceuticals: “Priori Bonds” will be suspended from trading and stock conversion will be suspended from May 6, 2024
Hainan Puli Pharmaceutical Co., Ltd. announced that due to the inability of Hainan Puli Pharmaceutical Co., Ltd. to disclose the 2023 annual report and the first quarter report of 2024 within the legal period (April 30, 2024), trading of the company's shares and convertible corporate bonds (bond abbreviation: Pulley Convertible, Bond Code: 123099) will be suspended from May 6, 2024. According to regulations: “Where stock trading of a listed company is suspended and resumed, trading of its convertible bonds is suspended or resumed at the same time.” As a result, during the stock suspension period, “Pulley Convertible Bonds” was suspended and stock conversion was suspended.
Express News | Puli Pharmaceuticals: Unable to disclose the 2023 Annual Report and the suspension of trading of stocks and convertible bonds reported for the first quarter of 2024 within the statutory period
The China Securities Convertible Index opened up 0.06%. Kai Convertible Bonds rose more than 8%, Zhengdan Convertible bonds rose 5%, and Puli Convertible bonds fell by more than 8%.
The China Securities Convertible Index opened up 0.06%. Kai Convertible Bonds rose more than 8%, Zhengdan Convertible bonds rose 5%, and Puli Convertible bonds fell by more than 8%.
China Securities Peng Yuan: Concerned that Puli Pharmaceuticals has received a decision on administrative supervision measures
China Securities Peng Yuan is concerned that according to the “Notice of Hainan Puli Pharmaceutical Co., Ltd. on Receiving the Hainan Securities Regulatory Bureau's Decision to Order the Company to Correct Administrative Supervision Measures” issued by Puli Pharmaceuticals on April 16, 2024, the Hainan Securities Regulatory Bureau issued a “Decision on Ordering Corrective Measures against Hainan Puli Pharmaceutical Co., Ltd.”, decided to take corrective administrative supervision measures against the company, and recorded the relevant irregularities in the capital market integrity file database. At the same time, the company was required to submit a rectification report to the Hainan Securities Regulatory Bureau within 30 days from the date of receipt of the decision. Depending on the follow-up inspection, the Supervisory Authority will review
Express News | Pri Pharmaceuticals: Oseltamivir phosphate capsules obtained marketing approval from the State Drug Administration
Express News | Puli Pharmaceuticals recently won a large order of 100 million yuan in the US market for iopamol injections
Prednisolone Pharmaceuticals (300630.SZ): Voriconazole injection was approved for marketing by the Norwegian Medicines Agency
Puri Pharmaceuticals (300630.SZ) announced that the company recently received a voriconazole injection issued by the Norwegian Medicines Agency...
A-share changes | Receiving a letter of concern Puli Pharmaceuticals once fell more than 15%, ranking first in the market with a decline of more than 15%
Glonghui, April 17 | Puli Pharmaceuticals (300630.SZ) fell sharply by more than 16% at the beginning of the session, leading the decline in the market. The decline has now narrowed to 10% to 14.5 yuan, with a total market value of 6.5 billion yuan. The Shenzhen Stock Exchange issued an announcement. Hainan Puli Pharmaceutical received the “Decision on Ordering Corrective Measures against Hainan Puli Pharmaceutical” issued by the Hainan Regulatory Bureau. According to the decision, the Hainan Securities Regulatory Bureau discovered during an on-site inspection that the disclosure of financial information such as operating income and profit in the 2021 and 2022 annual reports of Puli Pharmaceuticals was inaccurate.
Express News | Puri Pharmaceuticals was drastically lowered by more than 16%, and the company was ordered to be corrected by the Securities Regulatory Commission due to information disclosure violations.
The annual report letter discloses that Puli Pharmaceuticals (300630.SZ) was ordered by the Hainan Securities Regulatory Bureau to decide on corrective measures
Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received Hainan supervision from the China Securities Regulatory Commission...
Express News | Puri Pharmaceuticals: A supplementary application for new specifications for iopamol injections obtained FDA marketing approval
Express News | Prednisolone Pharmaceuticals: Voriconazole injections obtained marketing approval from the Finnish National Medicines Agency
No Data